A 45-year-old woman undergoes breast-conserving surgery with axillary clearance for a 2.8-cm invasive carcinoma of the breast. Histopathology confirms metastatic involvement of two axillary lymph nodes. Immunohistochemistry demonstrates expression of hormone receptors, while testing for HER2 overexpression is negative. She continues to have regular menstrual cycles following completion of adjuvant chemotherapy. Which of the following is the most appropriate adjuvant systemic therapy to reduce the risk of disease recurrence?
September 2, 2026 17
